Abstract

The current treatment approaches for allergic rhinitis are practiced over decades, but the patient quality of life has not yet changed so much. The reasons are research gaps in pathophysiology of the disease, proper management of the disease. Fexofenadine HCl is a second-generation antihistamine drug which has a half-life of about 14.4 h. It is useful in the management of common symptoms like sneezing, itchy throat, and red eyes in individuals suffering from allergic rhinitis. Fexofenadine immediate release or sustained release formulations are available in the market as suspension, tablet and capsule. In this research paper, we have discussed the symptoms associated with allergic rhinitis and treatment approaches. Fexofenadine HCl is being used for the treatment of this disease. But as it has a long half-life, we have discussed the importance of the introduction of sustained-release microsphere formulation of Fexofenadine HCl in the market.

Highlights

  • Allergic rhinitis is one of the most common chronic conditions in the world [1,2,3]

  • We have explored the published research of last 20 y to interpret the changes, advancement and limitation is the management of allergic rhinitis

  • Antihistamines are widely used in the treatment of allergic rhinitis

Read more

Summary

Introduction

Allergic rhinitis is one of the most common chronic conditions in the world [1,2,3]. Previously first-generation antihistamines were used for its management [4,5,6]. Due to sedative side effects, second-generation antihistamines are being used. Fexofenadine HCl is a second generation antihistamine drug [7,8,9,10]. Microspheres dosage forms of Fexofenadine HCl is expected to be convenient to have the maximum use of the given dose with sustained effects.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call